Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 25;8(30):50240-50251.
doi: 10.18632/oncotarget.16933.

Micrornas in prostate cancer: an overview

Daniela Vanacore  1   2 , Mariarosaria Boccellino  2 , Sabrina Rossetti  1   3 , Carla Cavaliere  1   4 , Carmine D'Aniello  1   5 , Rossella Di Franco  1   6 , Francesco Jacopo Romano  1 , Micaela Montanari  1   7 , Elvira La Mantia  1   8 , Raffaele Piscitelli  1   9 , Flavia Nocerino  1   10 , Francesca Cappuccio  1   11 , Giovanni Grimaldi  1   12 , Alessandro Izzo  1   12 , Luigi Castaldo  1   12 , Maria Filomena Pepe  1   8 , Maria Gabriella Malzone  1   8 , Gelsomina Iovane  3 , Gianluca Ametrano  1   6 , Paola Stiuso  2 , Lucio Quagliuolo  2 , Daniela Barberio  1   11 , Sisto Perdonà  12 , Paolo Muto  6 , Maurizio Montella  10 , Piera Maiolino  9 , Bianca Maria Veneziani  7 , Gerardo Botti  8   13 , Michele Caraglia  2 , Gaetano Facchini  1   3
Affiliations
Review

Micrornas in prostate cancer: an overview

Daniela Vanacore et al. Oncotarget. .

Abstract

Prostate cancer is the second highest cause of cancer mortality after lung tumours. In USA it affects about 2.8 million men and the incidence increases with age in many countries. Therefore, early diagnosis is a very important step for patient clinical evaluation and for a selective and efficient therapy. The study of miRNAs' functions and molecular mechanisms has brought new knowledge in biological processes of cancer. In prostate cancer there is a deregulation of several miRNAs that may function as tumour suppressors or oncogenes. The aim of this review is to analyze the progress made to our understanding of the role of miRNA dysregulation in prostate cancer tumourigenesis.

Keywords: biomarkers; microRNAs; oncogenic miRNAs; prostate cancer; tumor suppressor miRNAs.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. MiRNAs in PCa pathogenesis
Schematic representation of prostate cancer pathogenesis and miRNAs involved in this process. Cell cycle block and apoptosis resistance lead to cancer; afterwards, prostate cancer cells are subjected to epithelial mesenchymal transition (EMT), which confers increased migratory capacity and invasiveness to generate metastases. Over-expressed miRNAs are highlighted in red, down-expressed miRNAs are highlighted in green.
See this image and copyright information in PMC

References

    1. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361:859–64. - PubMed
    1. Caraglia M, Alaia C, Grimaldi A, Boccellino M, Quagliuolo L. MiRNA as prognostic and therapeutic targets in tumor of male urogenital tract. Mol Targets Strat Cancer Prev. 2016;7:151–171.
    1. Fong MK, Hare R, Jarkowski A. A new era for castrate resistant prostate cancer: a treatment review and update. J Oncol Pharm Pract. 2012;18:343–354. - PubMed
    1. Rodrigues DN, Butler LM, Estelles DL, de Bono JS. Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol. 2013;232:178–184. - PubMed
    1. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients, Phase I ZANTE Trial. Cancer Biol Ther. 2010;10:543–8. - PubMed